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CORRESPONDENCE 
Dear Editor
We appreciate the comments by Marcuzzi. Marcuzzi et al. (1) 
and we (2) showed that the pamidronate stimulates the secre-
tion of proinflammatory cytokines in mouse model and in hu-
man respectively. Although we measured the acute phase re-
sponse caused by intermittent large dose aminobisphosphate 
whereas Marcuzzi emphasized on the inflammatory effect of 
aminobisphosphate and its reversal by geraniol, the isoprenoid. 
Acute phase response, a notorious side effect of aminobisphos-
phate, typically occurs in about one third of patients taking ami-
nobisphophate for the first time (3). It was previously reported 
that after administration of large dose such as the dose for ma-
lignancy, proinflammatory cytokines were stimulated and thus, 
play a key role in acute phase response (4-6). We demonstrated 
the elevation of proinflammatory cytokines at the usual dose for 
osteoporosis. Marcuzzi et al. (1) successfully revealed that the 
inflammatory reaction caused by pamidronate could be allevi-
ated by geraniol and we hope that the exogenous geraniol could 
help to lessen the acute phase response. In conclusion, we both 
agree with induction of inflammatory response by pamidronate. 
Further investigation is required on finding the way to reduce 
the acute phase response that does not abrogate the therapeutic 
benefit of the aminobisphosphonate, including the exogenous 
geraniol.  
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